Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

CCardiff Oncology, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
C

Cardiff Oncology, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Expanded Access Program (EAP) of PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab for Treatment of Patients with KRAS-mutant Metastatic Colorectal Cancer
    May 14, 2021Cardiff Oncology

    The post Expanded Access Program (EAP) of PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab for Treatment of Patients with KRAS-mutant Metastatic Colorectal Cancer appeared first on Cardiff Oncology.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$1.08Close ยท Oct 9, 2026